RxDoctor Payments Data

Christopher Fisher, MD

Internal Medicine · Warr Acres, OKNPI 1306333414

Payments from drug & device makers

$1,445in general payments, 2019–2025

Across 18 payments — averaging $80.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medline Industries LP$1K
  • Molnlycke Health Care US, LLC$135
  • E.r. Squibb & Sons, L.L.C.$75
  • Smith+Nephew$48

What the payments were for

  • Travel & lodging$65946%
  • Food & beverage$77454%
  • Gifts$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,445 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$10,241,906
Medicare patients
689
Services billed
7,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$79,057
OzempicSemaglutide36$40,116
SantylCollagenase Clostridium Hist.31$31,562
ErtapenemErtapenem Sodium48$24,812
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen642$21,243
Sevelamer Hcl20$21,042
TrulicityDulaglutide19$19,273
MounjaroTirzepatide18$18,002
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen263$11,650
XareltoRivaroxaban44$11,411
JardianceEmpagliflozin39$10,458
MyrbetriqMirabegron39$9,143
Gabapentin454$8,791
Pantoprazole Sodium130$7,280
Budesonide33$6,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$48$31,56231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Warr Acres

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →